Literature DB >> 1952821

Mitochondrial oxidative phosphorylation defects in Parkinson's disease.

J M Shoffner1, R L Watts, J L Juncos, A Torroni, D C Wallace.   

Abstract

Parkinson's disease has been associated with defects in oxidative phosphorylation (Oxphos). We analyzed mitochondria isolated from muscle biopsies of 6 patients with Parkinson's disease for deficiencies in Oxphos enzymes and for mutations in the mitochondrial DNA. Oxphos enzyme assays were compared to the 5 to 95% confidence intervals from 16 control subjects. Four patients had complex I defects, whereas 1 patient had a complex IV defect. A genetic basis for Parkinson's disease was suggested by the presence of affected relatives of 2 patients with Parkinson's disease. Known pathological mitochondrial DNA mutations (insertion-deletions or point mutations) were not found. We conclude that Parkinson's disease is a systemic disorder of Oxphos, probably of a complex genetic etiology. Premature cell death in the nigrostriatal dopamine pathway could be due to energetic impairment and accentuated free radical generation caused by an Oxphos defect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952821     DOI: 10.1002/ana.410300304

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  67 in total

1.  Exercise test in Parkinson's disease.

Authors:  I Reuter; M Engelhardt; J Freiwaldt; H Baas
Journal:  Clin Auton Res       Date:  1999-06       Impact factor: 4.435

Review 2.  Somatic mutations in aging, cancer and neurodegeneration.

Authors:  Scott R Kennedy; Lawrence A Loeb; Alan J Herr
Journal:  Mech Ageing Dev       Date:  2011-11-03       Impact factor: 5.432

Review 3.  Diseases resulting from mitochondrial DNA point mutations.

Authors:  D C Wallace; M T Lott; J M Shoffner; M D Brown
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  The sequence of human mtDNA: the question of errors versus polymorphisms.

Authors:  N Howell; D A McCullough; I Kubacka; S Halvorson; D Mackey
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

5.  [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study.

Authors:  D S Higgins; J T Greenamyre
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

Review 6.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

7.  Complex I deficiency in Parkinson's disease frontal cortex.

Authors:  W Davis Parker; Janice K Parks; Russell H Swerdlow
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

Review 8.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

9.  Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.

Authors:  K J Buck; S G Amara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

10.  Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

Authors:  D M Frim; T A Uhler; W R Galpern; M F Beal; X O Breakefield; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.